GSK’s elaborate product portfolio lacks support from scientists and medical science experts, which is why Emma Walmsley’s first executive measure is to induce new R&D panel for drug development.
Scientific shortfall is a jeopardizing concern for growth any pharmaceutical company as sans scientific backing, development of drugs will endure an out-and-out inefficiency. Former chief financial officer of Merck & Co., Inc., Emma Walmsley, has been recently named as the new CEO for GlaxoSmithKline (GSK), and this CEO replacement move has shed the light on important shortcomings in the pharma company’s drug development operations. According to reports, the newly-appointed CEO has pointed out that the R&D-driven drugmaker needs more experienced researchers on medical science. While bringing with her an impressive commercial acumen from Merck, Walmsley intends to overcome GSK’s “lack of experience” by instating of new panel of medical science experts, which will involve some of the world’s leading scientists in the realm of infectious diseases.
GSK’s board of medical science experts is expected to be remodeled according to R&D-based inadequacies. The global drug manufacturer has also announced that prominent scientist and former FDA chief, Jesse Goodman, will chair GSK’s science committee. While Walmsley is slated to replace the present CEO Sir Andrew Witty by March 2017, the company has already commenced its measures to scout the best scientific personnel for its R&D operations. Reports also suggest GSK’s new science committee to provide the company’s business infrastructure with pharmaceutical and medical science management expertise. Joining Goodman will be Imperial College London’s professor Sir Roy Anderson. The British pharmaceuticals manufacturer will also appoint another former Merck CFO, Judy Lewent in its science committee. Present R&D president Patrick Vallance and board member Moncef Slaoui will also be strategically repositioned by GSK.
GSK’s soon-to-be CEO has expressed her qualms while leaving L’Oréal for GSK a few years back. However, the drugmaking giant is positive about having Walmsley onboard for expanding their business in China and European nations, focusing primarily on strengthen consumer health measures. With the instatement of a fresh science committee, GSK aims at diversifying its R&D for development of low-price, innovative and high-volume vaccines, pharmaceuticals, and consumer health products.